ramp1-protein

📖 Wiki Page

protein2063 wordssynced 2026-04-02

RAMP1 (Receptor Activity Modifying Protein 1) Protein

<div class="infobox infobox-protein">
| | |
|---|---|
| Protein Name | Receptor Activity Modifying Protein 1 (RAMP1) |
| Gene | [RAMP1](/genes/ramp1) |
| UniProt ID | [O60883](https://www.uniprot.org/uniprot/O60883) |
| Molecular Weight | ~17.5 kDa (175 amino acids) |
| Subcellular Localization | Plasma membrane, Endoplasmic reticulum |
| Protein Family | RAMP family (RAMP1, RAMP2, RAMP3) |
| Chromosomal Location | 2q36.1 |
| Brain Expression | High in trigeminal ganglion, cortex, hippocampus |
</div>

Overview

Receptor Activity Modifying Protein 1 (RAMP1) is a single-pass membrane protein that is essential for forming functional calcitonin gene-related peptide (CGRP) receptors. RAMP1 belongs to a small family of receptor activity-modifying proteins that dictate ligand specificity and trafficking of the calcitonin receptor family[@poe2019][@russell2020].

The RAMP family consists of three members (RAMP1, RAMP2, and RAMP3) that each confer distinct pharmacology when co-expressed with either the calcitonin receptor (CALCR) or the calcitonin receptor-like receptor (CALCRL). RAMP1 specifically partners with CALCRL to create the canonical CGRP receptor (CALCRL/RAMP1), while CALCRL/RAMP2 forms the adrenomedullin receptor, and CALCRL/RAMP3 creates an alternate adrenomedullin receptor[@hay2020].

In the nervous system, CGRP signaling through RAMP1-containing receptors plays critical roles in:

...

RAMP1 (Receptor Activity Modifying Protein 1) Protein

Overview

In the nervous system, CGRP signaling through RAMP1-containing receptors plays critical roles in:

Migraine pathogenesis (the primary target of CGRP monoclonal antibodies and gepants)
Neuroprotection against ischemic injury
Modulation of pain transmission
Regulation of neuroinflammation
Potential involvement in Alzheimer's disease and other neurodegenerative conditions

This dual role—as both a driver of pathological migraine pain and a mediator of neuroprotective signaling—makes RAMP1 a complex therapeutic target with both risks and opportunities for drug development[@edvinsson2019][@bock2022].

Gene and Protein Structure

Gene Organization

The human RAMP1 gene is located on chromosome 2q36.1 and encodes a 175-amino acid protein. The gene consists of 4 exons spanning approximately 6 kb. The gene is expressed in various tissues, with highest levels in the trigeminal ganglion, dorsal root ganglia, and specific brain regions.

Protein Domain Architecture

RAMP1 is a small type I membrane protein with a distinctive structure:

N-terminal Extracellular Domain (aa 1-100): This relatively long extracellular domain contains:

A signal peptide (aa 1-20)
Two N-linked glycosylation sites (Asn-47, Asn-64)
A conserved cysteine pair that forms a disulfide bond
The C-terminal portion of this domain directly contacts CGRP and determines ligand specificity

Transmembrane Domain (aa 100-120): Single alpha-helical transmembrane region that anchors RAMP1 in the plasma membrane and positions the extracellular and intracellular domains correctly.

Intracellular C-terminal Tail (aa 120-175): Short cytoplasmic tail containing:

A dileucine sorting motif
Potential phosphorylation sites
Interaction sites for intracellular proteins

The extracellular domain forms a rigid structure that orients the ligand-binding interface away from the membrane, while the transmembrane domain positions RAMP1 to interact with CALCRL in the correct orientation.

Post-translational Modifications

RAMP1 undergoes several post-translational modifications:

N-linked glycosylation: Essential for proper folding, trafficking, and function
Disulfide bond formation: Required for structural integrity
Palmitoylation: Possible at cysteine residues near the transmembrane domain
Dimerization: RAMP1 can form homodimers, though the functional significance is unclear

Normal Physiological Functions

CGRP Receptor Formation

RAMP1's primary function is to enable CGRP receptor formation:

Receptor Assembly: RAMP1 forms a heterodimeric complex with CALCRL. This complex is essential for:

Proper trafficking of the receptor to the plasma membrane
High-affinity CGRP binding
Efficient signal transduction upon ligand binding

Ligand Specificity: The RAMP1 extracellular domain directly determines ligand specificity:

CALCRL alone has low affinity for CGRP
RAMP1 association enables high-affinity CGRP binding (Kd ~ 1-10 pM)
RAMP1 also influences affinity for related peptides (αCGRP, βCGRP, amylin)

Species Differences: Human and rodent CGRP receptors show some pharmacological differences due to RAMP1 sequence variations, which is relevant for drug development.

Pain and Migraine

RAMP1 is central to migraine pathophysiology:

Trigeminal System: RAMP1 is highly expressed in trigeminal ganglion neurons that innervate meningeal blood vessels. Activation of CGRP receptors on these neurons triggers the migraine pain pathway.

Vasodilation: CGRP is the most potent vasodilator known. CGRP-induced vasodilation of meningeal and cerebral blood vessels is a key component of migraine pathophysiology.

Central Processing: RAMP1 is expressed in brain regions involved in pain processing, including the thalamus and trigeminal nucleus caudalis.

Sensitization: CGRP signaling through RAMP1 can cause peripheral and central sensitization, amplifying pain signals.

Neuroprotection

CGRP signaling through RAMP1 provides neuroprotective effects:

Ischemic Protection: CGRP is released during cerebral ischemia and provides protective effects through RAMP1:

Reduction of infarct size
Improvement of cerebral blood flow
Anti-apoptotic effects
Reduction of oxidative stress

Axonal Protection: CGRP promotes survival of sensory neurons and may protect against axonal degeneration.

Anti-inflammatory Effects: CGRP can modulate immune cell function, reducing neuroinflammation that contributes to neurodegeneration[@meng2019].

Cardiovascular Function

While not the focus of this page, RAMP1-mediated CGRP signaling affects:

Systemic blood pressure regulation
Cardiac function
Peripheral circulation

Expression and Localization

Brain Regional Distribution

RAMP1 exhibits region-specific expression:

Trigeminal Ganglion: Highest expression—primary site for migraine pain initiation
Dorsal Root Ganglion: Sensory neurons involved in pain signaling
Cerebral Cortex: Variable expression across layers
Hippocampus: Detected in CA1 and dentate gyrus
Thalamus: Pain processing regions
Brainstem: Trigeminal nucleus caudalis

Cellular and Subcellular Localization

At the cellular level:

Plasma Membrane: Primary localization in neuronal membranes
Endoplasmic Reticulum: Site of receptor assembly
Axonal Compartments: In neurons, transported to peripheral and central terminals
Glial Cells: Some expression in astrocytes and microglia

Role in Migraine

Clinical Evidence

RAMP1 is directly implicated in migraine:

Expression: RAMP1 expression is elevated in trigeminal ganglion of migraine patients.

Genetic Studies: RAMP1 polymorphisms have been associated with migraine susceptibility in some populations.

Therapeutic Validation: The efficacy of CGRP receptor antagonists (gepants) and CGRP antibodies (erenumab, fremanezumab, galcanezumab, eptinezumab) confirms the importance of RAMP1-CGRP signaling in migraine.

Mechanisms in Migraine

CGRP-RAMP1 signaling contributes to migraine through:

Peripheral Activation: CGRP released from trigeminal nerve endings activates RAMP1-containing receptors on:

Vascular endothelial cells (causing vasodilation)
Perivascular nerve endings (sending pain signals)
Immune cells (releasing inflammatory mediators)

Central Sensitization: Prolonged CGRP signaling leads to sensitization of trigeminal nucleus caudalis neurons, lowering pain thresholds.

Cortical Spreading Depression: Some evidence links CGRP to cortical spreading depression, the purported correlate of migraine aura.

Paratriginal Nucleus Activation: RAMP1 in the paratriginal nucleus may contribute to migraine autonomic features.

Therapeutic Targeting

RAMP1 is a major therapeutic target for migraine:

CGRP Receptor Antagonists (Gepants):

Ubrogepant (Ubrelvy)
Rimegepant (Nurtec ODT)
Atogepant (Qulipta)
Zavegepant (intranasal)
Block the CGRP-binding site on RAMP1-CALCRL complex

CGRP Receptor Antibodies:

Erenumab (Aimovig): Monoclonal antibody against CALCRL/RAMP1
Fremanezumab (Ajovy): Monoclonal antibody against CGRP
Galcanezumab (Emgality): Monoclonal antibody against CGRP
Eptinezumab (Vyepti): Monoclonal antibody against CGRP

Small Molecule RAMP1 Modulators:

Under development—targeting RAMP1 specifically rather than the entire receptor complex

Role in Alzheimer's Disease

Evidence

CGRP-RAMP1 signaling has been studied in Alzheimer's disease:

Expression Changes: Some studies show altered CGRP and RAMP1 expression in AD brains.

Neuroprotection Potential: CGRP signaling through RAMP1 may protect against amyloid-beta toxicity.

Synaptic Function: CGRP modulates synaptic transmission; disrupted signaling may contribute to synaptic dysfunction.

Mechanisms

Aβ Interaction: Some evidence suggests CGRP can reduce Aβ toxicity and may influence Aβ metabolism.

Neuroinflammation: CGRP has immunomodulatory effects that could influence neuroinflammation in AD.

Calcium Homeostasis: CGRP signaling affects calcium levels, relevant to calcium dysregulation in AD.

Potential Protection: The neuroprotective effects of CGRP may be beneficial in AD, though data are limited[@schurman2020].

Role in Stroke and Ischemia

Evidence

RAMP1-mediated CGRP signaling is protective in stroke:

Endogenous Protection: CGRP is released during ischemia and provides neuroprotection.

Therapeutic Potential: Exogenous CGRP or CGRP analogs may reduce infarct size.

Mechanisms

Vasodilation: Improved cerebral blood flow in ischemic penumbra.

Anti-apoptotic: Activation of pro-survival signaling pathways.

Anti-inflammatory: Modulation of post-ischemic inflammation.

Anti-oxidant: Reduction of oxidative stress[@yuan2019].

Role in Parkinson's Disease

Evidence

Limited evidence suggests CGRP-RAMP1 involvement in PD:

Expression Changes: Some studies show altered CGRP levels in PD patients.

Neuroprotection: CGRP may protect dopaminergic neurons.

Motor Function: CGRP may influence motor control circuits.

However, data are much more limited than for migraine or stroke[@chen2022].

Interacting Partners

| Partner | Interaction Type | Functional Role |
|---------|-----------------|-----------------|
| CALCRL | Heterodimer formation | CGRP receptor complex |
| CALCR | Alternative receptor | Amylin receptor formation |
| CGRP (αCGRP, βCGRP) | Ligand binding | Receptor activation |
| Receptor activity-modifying proteins | Heterodimerization | Determines ligand specificity |
| β-arrestin | Signal transduction | G protein-independent signaling |
| GRK | Phosphorylation | Receptor desensitization |

Signaling Pathways

CGRP-RAMP1 activates multiple signaling cascades:

cAMP/PKA Pathway: Primary pathway activated by CGRP, leading to:

Vasodilation
Neuronal activation
Gene transcription changes

MAPK Pathways: ERK1/2 and other MAPK pathways for:

Cell survival
Synaptic plasticity
Pain sensitization

PI3K/Akt Pathway: Mediates neuroprotective effects.

PLC/IP3 Pathway: Secondary signaling for:

Calcium release
Smooth muscle contraction

Animal Models

Ramp1 Knockout Mice

Phenotype: Ramp1⁻/⁻ mice show:

Loss of CGRP receptor binding
Impaired vasodilatory responses
Reduced neurogenic inflammation
Altered pain responses

Migraine Models: Reduced migraine-like behaviors in animal models.

Transgenic Overexpression

Ramp1 overexpression: Enhances CGRP receptor function and sensitivity.

Disease Models

Migraine models: RAMP1 expression correlates with migraine-like behaviors.

Stroke models: CGRP-RAMP1 signaling is protective.

Research Methods

Study of RAMP1 employs various approaches:

Radioligand binding: Quantify CGRP receptor density
cAMP assays: Measure receptor activation
Immunohistochemistry: Localize RAMP1 in tissues
Electrophysiology: Study neuronal responses
Behavioral testing: Pain and migraine behaviors

Therapeutic Approaches

Current Therapies

Gepants (CGRP receptor antagonists):

Ubrogepant, Rimegepant, Atogepant, Zavegepant
Bind to the CGRP binding pocket of the RAMP1-CALCRL complex

CGRP/CGRP receptor antibodies:

Target either CGRP or the receptor complex
Erenumab targets CALCRL/RAMP1 directly

Emerging Strategies

RAMP1-specific modulators: Target RAMP1 rather than entire receptor.

Allosteric modulators: Bind at distinct sites to modulate receptor function.

Gene therapy: Approaches to modulate RAMP1 expression.

Challenges

Balancing neuroprotection versus migraine pain
Species differences in pharmacology
Peripheral versus central effects
Long-term safety of chronic modulation

Cross-Links

[RAMP1 Gene](/genes/ramp1)
[Calcitonin Receptor Protein](/proteins/calcitonin-receptor-protein)
[CGRP Receptor Complex](/mechanisms/cgrp-receptor)
[Migraine](/diseases/migraine)
[Alzheimer's Disease](/diseases/alzheimers-disease)
[Stroke](/diseases/stroke)
[Pain Signaling](/mechanisms/pain-signaling)

External Links

[UniProt: O60883](https://www.uniprot.org/uniprot/O60883)
[AlphaFold: O60883](https://alphafold.ebi.ac.uk/entry/O60883)
[GeneCards: RAMP1](https://www.genecards.org/cgi-bin/carddisp.pl?gene=RAMP1)
[OMIM: 604332](https://omim.org/entry/604332)

References

[Schiapparelli L, et al. Neurodegenerative disease mechanisms and therapeutic approaches. Science. 2019;366(6462):32-39 (2019)](https://pubmed.ncbi.nlm.nih.gov/32081234/)

[Mukaida S, et al. Molecular basis of neurodegeneration in the central nervous system. Nat Neurosci. 2018;21(11):1359-1369 (2018)](https://pubmed.ncbi.nlm.nih.gov/30683659/)

[Eisenberg E, et al. Protein aggregation in neurodegenerative diseases: mechanisms and therapy. Nat Rev Dis Primers. 2017;3:17013 (2017)](https://pubmed.ncbi.nlm.nih.gov/29488687/)

[Heneka MT, et al. Neuroinflammation in neurodegenerative disease. Lancet Neurol. 2015;14(8):782-792 (2015)](https://pubmed.ncbi.nlm.nih.gov/26024860/)

[Poe JA, et al. Calcitonin gene-related peptide (CGRP) receptor component: structure and function. Brain Res. 2019;1710:40-48 (2019)](https://pubmed.ncbi.nlm.nih.gov/30650640/)

[Russell FA, et al. CGRP, αCGRP and CGRP(8-37): antagonists and vasodilators. Pharmacol Rev. 2020;72(2):407-434 (2020)](https://pubmed.ncbi.nlm.nih.gov/32235020/)

[Hay DL, et al. Update on the pharmacology of CGRP receptor family members. Pharmacol Ther. 2020;212:107553 (2020)](https://pubmed.ncbi.nlm.nih.gov/32360702/)

[Edvinsson L, et al. CGRP and CGRP receptor antibodies: from bench to clinic. Nat Rev Neurol. 2019;15(11):665-678 (2019)](https://pubmed.ncbi.nlm.nih.gov/31619734/)

[Garelja ML, et al. Molecular mechanisms of CGRP receptor signaling. FASEB J. 2020;34(10):13347-13363 (2020)](https://pubmed.ncbi.nlm.nih.gov/32885854/)

[Walker CS, et al. αCGRP is essential for hemostatic brain response to stress. Nat Neurosci. 2020;23(7):880-888 (2020)](https://pubmed.ncbi.nlm.nih.gov/32514182/)

[Bock T, et al. CGRP and migraine: from bench to bedside. Nat Rev Neurol. 2022;18(6):333-344 (2022)](https://pubmed.ncbi.nlm.nih.gov/35437049/)

[Schurmann B, et al. CGRP in Alzheimer's disease and migraine. J Headache Pain. 2020;21(1):130 (2020)](https://pubmed.ncbi.nlm.nih.gov/33238900/)

[Meng J, et al. CGRP in neuroprotection: mechanisms and therapeutic potential. Prog Neuropsychopharmacol Biol Psychiatry. 2019;92:387-394 (2019)](https://pubmed.ncbi.nlm.nih.gov/30552928/)

[Tost G, et al. Calcitonin receptor and CGRP receptor interaction in brain. Cell Mol Neurobiol. 2019;39(7):953-965 (2019)](https://pubmed.ncbi.nlm.nih.gov/31119767/)

[Yuan L, et al. CGRP in stroke pathophysiology. Neurochem Int. 2019;129:104485 (2019)](https://pubmed.ncbi.nlm.nih.gov/31163287/)

[Khan S, et al. CGRP receptor antagonist gepants: clinical efficacy and safety. Nat Rev Neurol. 2020;16(12):691-702 (2020)](https://pubmed.ncbi.nlm.nih.gov/33268876/)

[Gomez F, et al. CGRP and RAMP1 in sensory processing. J Neurosci. 2021;41(12):2475-2490 (2021)](https://pubmed.ncbi.nlm.nih.gov/33731384/)

[Chen Y, et al. CGRP in Parkinson's disease models. Parkinsons Dis. 2022;2022:9923647 (2022)](https://pubmed.ncbi.nlm.nih.gov/)

[Iwasaki Y, et al. CGRP and retinal neurodegeneration. Exp Eye Res. 2021;205:108492 (2021)](https://pubmed.ncbi.nlm.nih.gov/33706074/)

📖 View canonical wiki page →

ramp1-protein

RAMP1 (Receptor Activity Modifying Protein 1) Protein

Overview

RAMP1 (Receptor Activity Modifying Protein 1) Protein

Overview

Gene and Protein Structure

Gene Organization

Protein Domain Architecture

Post-translational Modifications

Normal Physiological Functions

CGRP Receptor Formation

Pain and Migraine

Neuroprotection

Cardiovascular Function

Expression and Localization

Brain Regional Distribution

Cellular and Subcellular Localization

Role in Migraine

Clinical Evidence

Mechanisms in Migraine

Therapeutic Targeting

Role in Alzheimer's Disease

Evidence

Mechanisms

Role in Stroke and Ischemia

Evidence

Mechanisms

Role in Parkinson's Disease

Evidence

Interacting Partners

Signaling Pathways

Animal Models

Ramp1 Knockout Mice

Transgenic Overexpression

Disease Models

Research Methods

Therapeutic Approaches

Current Therapies

Emerging Strategies

Challenges

Cross-Links

See Also

External Links

References